“The present condition has exposed some structural weaknesses inside the EU’s medicines supply chain and a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides mentioned. She encouraged that offer chain issues be addressed in an EU pharmaceutical method predicted to be released by the tip